Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Omeros Corporation - Common Stock
(NQ:
OMER
)
16.38
-0.79 (-4.60%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Omeros Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
May 12, 2025
From
Omeros Corporation
Via
Business Wire
Top movers analysis one hour before the close of the markets on 2025-05-12: top gainers and losers in today's session.
↗
May 12, 2025
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Via
Chartmill
Which stocks are moving on Monday?
↗
May 12, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via
Chartmill
What's Next: Omeros's Earnings Preview
↗
March 28, 2025
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
May 12, 2025
Via
Benzinga
These stocks are gapping in today's session
↗
May 12, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
May 12, 2025
From
Omeros Corporation
Via
Business Wire
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
May 06, 2025
From
Omeros Corporation
Via
Business Wire
Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
April 28, 2025
Via
Benzinga
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
↗
April 11, 2025
Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells.
Via
Benzinga
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
April 10, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
April 08, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
March 31, 2025
From
Omeros Corporation
Via
Business Wire
Earnings Scheduled For March 31, 2025
↗
March 31, 2025
Via
Benzinga
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings
↗
March 28, 2025
Via
Benzinga
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
March 26, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
March 21, 2025
From
Omeros Corporation
Via
Business Wire
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
March 17, 2025
Via
Benzinga
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
↗
March 17, 2025
Via
Benzinga
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
March 13, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
February 20, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
February 14, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
February 10, 2025
From
Omeros Corporation
Via
Business Wire
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
January 16, 2025
From
Omeros Corporation
Via
Business Wire
This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
December 23, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
December 19, 2024
Via
Benzinga
Nasdaq Jumps 100 Points, US Initial Jobless Claims Decline
↗
December 19, 2024
Via
Benzinga
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges
↗
December 19, 2024
Omeros announces positive results from a pivotal narsoplimab trial in TA-TMA, showing significant survival benefits and advancing regulatory submissions.
Via
Benzinga
Gold Falls Sharply, Lamb Weston Shares Plunge
↗
December 19, 2024
Via
Benzinga
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
↗
December 19, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.